Theracor Receives FDA Clearance: A New Era for Wound Care
StimLabs has achieved a remarkable milestone with the FDA granting 510(k) clearance to Theracor™, a groundbreaking medical device made from human umbilical cord-derived extracellular matrix. This innovative product comes in sheet form and represents a pivotal advancement for the wound care sector. The acceptance of Theracor not only reinforces StimLabs' leadership in this field but also expands their suite of products designed to meet diverse patient needs.
About Theracor: Features and Benefits
Theracor is specifically created to offer a protective and moist environment for wounds. It serves multiple medical needs, aligning with the indications of its predecessor, Corplex P, which was the first FDA-cleared umbilical cord-derived device in a particulate format. This expansion allows healthcare providers to access a fully FDA cleared, continuous-format solution for various types of wounds, including partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, surgical wounds, trauma, and draining wounds.
Empowering Healthcare Providers
John Daniel, the CEO and Founder of StimLabs, emphasizes that the clearance of Theracor enhances the options available for clinicians and patients. The aim is to cater to the needs of patients suffering from both acute and chronic wounds, elevating the standard of care. The introduction of Theracor underscores their commitment to bridging gaps in clinical needs.
StimLabs and its Vision for Regenerative Medicine
Based in Roswell, Georgia, StimLabs is at the forefront of regenerative medicine. The company's focus predominantly lies in the advanced treatment of wound care and surgical applications. By combining innovation with a strong intellectual property foundation, they ensure that they continuously provide effective solutions for various clinical challenges.
Revolutionizing Wound Care Solutions
With Theracor’s recent FDA clearance, StimLabs aims to further its mission of improving care for patients with wounds that require specialized treatments. The unique properties of Theracor allow it to cover wounds effectively while supporting metabolic processes that enhance healing. By introducing this sheet device, StimLabs aligns with its vision to offer comprehensive solutions to healthcare providers nationwide.
Availability and Future Directions
Theracor is set to become available in medical settings shortly, highlighting StimLabs' ongoing commitment to innovation in healthcare. The company is on a continuous journey to develop solutions that not only meet the needs of today but also anticipate the clinical challenges of tomorrow.
Connecting with StimLabs
For those interested in learning more about Theracor, StimLabs encourages inquiries about their product portfolio and ongoing projects. The company strives to create a positive impact in their community by empowering healthcare providers with advanced medical solutions.
Frequently Asked Questions
What is Theracor?
Theracor is an FDA-cleared medical device made from human umbilical cord extracellular matrix, designed to treat various types of wounds.
How does Theracor differ from Corplex P?
While Corplex P is a particulate format, Theracor is available as a continuous sheet, providing enhanced options for wound management.
Who can benefit from Theracor?
Clinicians treating patients with acute and chronic wounds, such as pressure ulcers and surgical wounds, can benefit from Theracor’s innovative design.
When will Theracor be available?
Theracor is expected to be available soon for use in medical settings, further expanding StimLabs' product offerings.
How does StimLabs support clinicians?
StimLabs is dedicated to providing advanced solutions to meet unmet clinical needs while empowering healthcare professionals with innovative products.
